Ipamorelin powder is a synthetic pentapeptide growth hormone secretagogue (GHS) and a selective agonist of the ghrelin receptor GHSR-1a. Its greatest research value lies in its ability to significantly promote GH pulse release while having minimal impact on ACTH/cortisol and prolactin levels, making it suitable as a relatively pure tool for GH axis intervention and reducing non-specific endocrine noise. As a lyophilized powder, it offers good stability and ease of transport, and is commonly used in mechanistic studies of endocrine physiology, bone metabolism, muscle metabolism, and pharmacological models.
Unlock cleaner endocrine research with Shaanxi Medibridge Ipamorelin (purity ≥99.15%). HPLC/LC‑MS verified, RUO, batch‑traceable, low endotoxin options. Lyophilized for stability, low‑adsorption packaging, and fast global shipping.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Ipamorelin |
170851-70-4 |
MB2508151786 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2025-08-15 |
2025-08-16 |
2027-08-14 |
|
Sample Qty Base |
Packing |
Test Method |
|
40.32 KGS |
25Gs/BOTTLE |
HPLC |
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.92% |
|
Peptide Assay |
≥80% |
89.65% |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
salt |
<5.0% |
2.13% |
|
Water |
≤9.0% |
3.01% |
|
Residual Solvent |
||
|
Methanol |
≤0.3% |
Complies |
|
Isopropanol |
≤0.5% |
Complies |
|
Acetonitrile |
≤0.041% |
0.021% |
|
Methylene Chloride |
≤0.06% |
0.033% |
|
N,N-Dimethylformamide |
≤0.088% |
Complies |
|
Triethylamine |
≤0.032% |
Complies |
|
Tert-butyl methyl ether |
≤0.5% |
0.301% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Specifications (for research use only)
Why choose us
1. High Selectivity for GH Promotion: Selectively activates GHSR-1a, resulting in clear GH pulse signals.
2. Excellent Lyophilization Stability: Low-moisture lyophilization process ensures robust transport and long-term storage.
3. Strict Quality Control: Each batch comes with a Certificate of Analysis (COA) containing HPLC main peak purity, LC-MS identification, and peptide content correction coefficients.
4. Low Adsorption Packaging: Neutral borosilicate glass vials with low adsorption, nitrogen-filled and tamper-evident seals, minimizing peptide adsorption loss under low-concentration conditions.
5. Salt Form and Residue Optimization: Defaults to acetate or low-TFA solutions, with optional salt form replacement; provides residual solvent data for cellular and in vivo studies.
6. Reconstitution Friendly: Offers suggestions for working solutions containing HSA/BSA to reduce adsorption on the container walls.
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.96% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Typical Applications
In layman's terms
Ipamorelin powder is a pentapeptide that mimics ghrelin, specifically activating GHSR-1a to induce pituitary GH release, while minimizing the activation of bypass hormones like cortisol and prolactin, resulting in a cleaner signal.
Receptor and Pathway
As a selective GHSR-1a (7TM GPCR) agonist, it primarily couples Gq/11 → PLC → IP3/DAG → Ca2+ mobilization and membrane depolarization, triggering exocytosis of growth hormone-producing cells. It can also reduce somatostatin tone and enhance the GHRH effect at the hypothalamic level, forming a dual-pathway amplification of "disinhibition + synergy".
Pulse and Rhythm
Ipamorelin enhances the amplitude and (in some models) frequency of GH pulses, with rapid onset and well-defined peak values, facilitating time-resolved kinetics and deconvolution analysis. Endogenous GH is active at night/during sleep; experiments should be conducted at fixed times to minimize circadian rhythm interference.
Selectivity Advantages
Compared to some older-generation GHS, Ipamorelin exhibits relatively weaker induction of ACTH/cortisol and PRL, with milder gastrointestinal/appetite effects, making it more suitable for "pure GH axis" studies.
Experimental Suggestions
To verify pathway specificity, GHRH analogs (synergistic enhancement), somatostatin analogs (antagonism), or GHSR inhibition tools/gene models (blockade) can be used in combination for mechanism localization; cellular/ex vivo pituitary glands can be analyzed using dual readouts of Ca2+ imaging and GH secretion assays.
Pharmacokinetics
Absorption
a. IV: Immediate exposure, suitable for mechanism/threshold and population pharmacokinetic/potential differentiation.
b. SC: Rapid peak concentration, easy to administer, commonly used in in vivo studies and time-resolved potential (PD).
c. IP (rodents): Suitable for research, with a slightly slower onset of action and greater variability than SC. Oral/nasal administration is usually insufficient and limited to exploratory applications.
Distribution
Primarily distributed in extracellular fluid, with low plasma protein binding; limited permeability to the BBB, mainly affecting the hypothalamus-pituitary axis indirectly.
Metabolism and Clearance
Rapidly degraded into amino acids/small peptides by peripheral and hepatic/renal peptidase-related enzymes, cleared via renal and hepatic pathways; CYP-mediated metabolism is negligible.
Half-life and linearity
These are short-lived peptides (commonly ranging from tens of minutes to several hours, varying depending on species, route of administration, and formulation); exposure is approximately linear, but at high doses, PD saturation causes the "effect-exposure" relationship to become non-linear.
Bioanalysis
LC-MS/MS or high-specificity immunoassays are recommended. Adding aprotinin to the sample can reduce in vitro degradation. Micro-blood sampling and population PK/PD (one-/two-compartment models, Emax linking) can improve parameter robustness.
Typical Research Application Scenarios(For academic exchange only, not for any clinical diagnosis)
Endocrine Physiology and Pharmacology
a. GH Pulse Dynamics: Using Ipamorelin to trigger and amplify pulses, combined with dense sampling and deconvolution/pulse analysis, to depict "peak height-frequency-AUC".
b. Synergistic/Antagonistic Validation: Combined with GHRH analogs (synergistic amplification), combined with somatostatin analogs or GHSR inhibitory tools (pathway localization).
c. Receptor Dynamics: Receptor occupancy-effect relationship, desensitization and internalization kinetics, response decay curves and recovery time with repeated dosing.
Bone and Muscle Metabolism
a. Bone Turnover: Short-term detection of P1NP/osteocalcin/CTX, long-term combined with μCT/bone mineral density and biomechanical testing; used for research on GH/IGF-1 axis regulation in glucocorticoid-induced bone changes and aging models.
b. Muscle protein turnover: Assessment of muscle mass, muscle fiber type, MuRF1/Atrogin-1 expression, and synthetic/degradative markers in muscle atrophy/aging models; can be combined with stable isotope tracing (e.g., phenylalanine incorporation).
Energy and metabolic diseases
a. Lipolysis and substrate utilization: NEFA/glycerol kinetics, indirect calorimetry (VO2/VCO2/RER), and energy expenditure; the impact of the GH axis on metabolic flexibility in dietary obesity and insulin resistance models.
b. Liver and fat: Assessment of the axial linkage between IGF-1 hepatic synthesis, fatty liver/liver lipid profiles, and lipid metabolism enzymes and inflammatory markers.
FAQ
Q: What does Ipamorelin do to the body?
A: As a selective GHSR-1a agonist, it has relatively weak effects on ACTH/cortisol and prolactin, resulting in a high signal-to-noise ratio. It is commonly used in endocrine dynamics and GH axis mechanism studies (RUO).
Q: Why did the FDA ban Ipamorelin?
A: It's not that it's "banned," but rather that it's not an FDA-approved drug for human use; it's not a compliant raw material that can be prepared in pharmacies, and its sale as a drug/health product would be subject to enforcement. It's compliantly distributed for "research use (RUO)," but prohibited for use in diagnosis, treatment, or diet.
Q: What are the downsides of Ipamorelin?
A: Studies have observed: injection site reactions, flushing/headache, mild sodium and water retention-like symptoms; short-term decreased insulin sensitivity and increased lipolysis (intrinsic GH effects); desensitization/weakened response with high-frequency dosing. Theoretically, careful assessment of tumor-related pathways is necessary.
Q: Will Ipamorelin help me lose weight?
A: There is no approved indication or sufficient clinical evidence to support its "weight loss efficacy." GH can promote lipolysis, but it may also reduce insulin sensitivity, cause fluid retention, and result in inconsistent weight changes. This product is for RUO only; research chemicals should not be used for personal weight loss.
Designed for robust GH/IGF‑1 studies, PK/PD profiling, and metabolism models-delivering high signal‑to‑noise and reproducible data. Choose higher purity. Choose Medibridge reliability. Comprehensive COA and responsive support included. Trusted by labs worldwide today.
If you're seeking a high quality Ipamorelin powder manufacturer for a long term, stable partnership, please contact us at hi@medibridgeapi.com or whatsApp: +44 07548632075.
Hot Tags: ipamorelin powder, China ipamorelin powder manufacturers, suppliers, factory, BPC 157 Powder, Survodutide Peptide, Ghrp Peptide, Selank Powder, Peptide SS 31, Thymosin Alpha 1 Peptide
